Achieving Target Infliximab Drug Concentrations Impr Biomarkers in Crohn's Disease

Inflammatory Bowel Diseases

27, 1045-1051

DOI: 10.1093/ibd/izaa241

Citation Report

#	Article	IF	Citations
1	Fool Me Once... Treatment Exposure to Achieve Remission in Pediatric IBD. European Journal of Pediatrics, 2020, 179, 1921-1924.	3.4	2
2	Therapeutic Drug Monitoring and Outcome of Infliximab Therapy in Pediatric Onset Inflammatory Bowel Disease. Frontiers in Pediatrics, 2021, 8, 623689.	2.4	17
3	Oncostatin-M Does Not Predict Treatment Response.... Journal of Pediatric Gastroenterology and Nutrition, 2021, 73, 352-357.	3.3	6
4	A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease. American Journal of Gastroenterology, 2021, 116, 2014.	5.8	201
5	Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease: Unmet Needs and Future Perspectives. The Lancet Gastroenterology and Hepatology, 2022, 7, 171-185.	29.4	169
6	Proactive Infliximab Optimisation Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Crohn's Disease: Study Protocol for a Randomised, Controlled, Multicentre, Open-Label Study (the OPTIMIZE Trial). BMJ Open, 2022, 12, e057656.	2.7	29
7	Pediatric Inflammatory Bowel Disease: Fecal Calprotectin Response to Anti-Tumor Necrosis Factor Alpha. Pediatric Research, 2023, 93, 131-136.	4.0	3
8	Therapeutic Drug Monitoring of Biologics in Crohn's Disease. Gastroenterology Clinics of North America, 2022, 51, 299-317.	3.6	12
9	Research Progress on the Relationship Between Intestinal Microecology and Intestinal Bowel Disease. Animal Models and Experimental Medicine, 2022, 5, 297-310.	4.1	68
10	Real World Population Pharmacokinetic Study in Children and Young Adults With Inflammatory Bowel Disease Discovers Novel Blood and Stool Microbial Predictors of Vedolizumab Clearance. Alimentary Pharmacology and Therapeutics, 2023, 57, 524-539.	7.7	26
11	Higher Postinduction Infliximab Concentrations Are Associated With Favorable Clinical Outcomes in Pediatric Crohn's Disease: A Post Hoc Analysis of the REACH Trial. American Journal of Gastroenterology, 2023, 118, 485.	5.8	7
12	90K/Mac-2 BP Is a New Predictive Biomarker of Response to Infliximab Therapy in IBD Patients. International Journal of Molecular Sciences, 2023, 24, 3955.	5.9	9
13	Infliximab Therapy for Pediatric Crohn Disease and Ulcerative Colitis. , 2023, .		0
14	Pursuing Neutrophils: Systematic Scoping Review on Blood-Based Biomarkers as Predictors of Treatment Outcomes in Inflammatory Bowel Disease. Therapeutic Advances in Gastroenterology, 2023, 16, 17562848231155987.	4.2	14
15	Precision Dosing of Anti-TNF Therapy in Pediatric Inflammatory Bowel Disease. Current Gastroenterology Reports, 2023, 25, 323-332.	4.9	14
16	. Chinese Journal of Contemporary Pediatrics, 2022, 24, 1246-1251.	0.5	0
17	De Novo Crohn's Disease Diagnosed in the Setting of Acute SARSCov- 2 Infection Requiring Escalation of Infliximab Therapy Guided by Personalized Pharmacokinetics. Journal of Pediatrics Perinatology and Child Health, 2024, 8, 1-4.	0.3	0
18	Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement From the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic Drug Monitoring, 2024, 46, 291.	2.2	26

#	Article	IF	Citations
19	Development and Validation of a Novel Criterion of Histologic Healing in Ulcerative Colitis Defined by Inflammatory Cell Enumeration in Lamina Propria Mucosa: A Multicenter Retrospective Cohort in China. Chinese Medical Journal, 2024, 137, 1316.	6.7	9
20	Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn's Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies. Journal of Crohn's and Colitis, 2025, .	8.8	5
21	Evaluation of Pharmacokinetic Metrics and Pharmacodynamic Biomarkers Associated With Endoscopic Healing in Pediatric Crohn's Disease Patients Treated With Anti-Tumor Necrosis Factor Biologics. Crohn's & Colitis 360, 2026, 8, otag088.	2.5	0
22	Model-Informed Precision Dosing Systems for Treatment of Inflammatory Bowel Disease. , 2026, .		0